EUVIMEDEUVIMED entdecken
Crossref

Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study

Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano

Biological and Pharmaceutical Bulletin · 2023

DOI: 10.1248/bpb.b22-00794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2023. Verfasst von Tomoki Hori und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nara Prefecture General Medical Center. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansRetrospective StudiesEast Asian PeopleProtein Kinase InhibitorsAniline CompoundsPrognosisMutationErbB ReceptorsExonsAcrylamidesIndolesPyrimidines

Stichwörter der Autor:innen

T790Mepidermal growth factor receptor–tyrosine kinase inhibitorexon 19 deletionnon-small cell lung cancerosimertinib

Substanzen

Protein Kinase InhibitorsAniline CompoundsErbB ReceptorsosimertinibAcrylamidesIndolesPyrimidinesEGFR protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, Nara Prefecture General Medical Center.
  • Department of Pharmacy, Kobe University Hospital.
  • Department of Respiratory Medicine, Nara Prefecture General Medical Center.

Zitieren

APA

Hori, T., Yamamoto, K., Ito, T., Ikushima, S., Omura, T., & Yano, I. (2023). Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b22-00794

Vancouver

Hori T, Yamamoto K, Ito T, Ikushima S, Omura T, Yano I. Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study. Biological and Pharmaceutical Bulletin. 2023. doi:10.1248/bpb.b22-00794

BibTeX
@article{Hori2023,
  author = {Hori, Tomoki and Yamamoto, Kazuhiro and Ito, Takefumi and Ikushima, Shigeki and Omura, Tomohiro and Yano, Ikuko},
  title = {Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2023},
  doi = {10.1248/bpb.b22-00794}
}
Kostenlos starten →